Stockscreener 앱 받기
23.98
1.05%
0.25
시간 외 거래:
23.98
전일 마감가:
$23.73
열려 있는:
$23.99
하루 거래량:
200.40K
Relative Volume:
0.59
시가총액:
$1.63B
수익:
$350.00K
순이익/손실:
$-72.78M
주가수익비율:
-22.20
EPS:
-1.08
순현금흐름:
$-54.46M
1주 성능:
+19.18%
1개월 성능:
+8.51%
6개월 성능:
+32.63%
1년 성능:
+38.69%
1일 변동 폭
$23.53
$24.20
1주일 범위
$19.30
$24.20
52주 변동 폭
$12.56
$26.30
펄스 바이오 Stock (PLSE) Company Profile
명칭
Pulse Biosciences Inc
전화
510-906-4600
주소
3957 POINT EDEN WAY, HAYWARD, CA
Compare PLSE vs ISRG, BDX, MDLN, ALC, RMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PLSE
Pulse Biosciences Inc
|
23.98 | 1.61B | 350.00K | -72.78M | -54.46M | -1.08 |
ISRG
Intuitive Surgical Inc
|
451.29 | 165.37B | 10.06B | 2.88B | 2.49B | 7.876 |
BDX
Becton Dickinson Co
|
156.69 | 45.13B | 21.92B | 1.76B | 2.63B | 6.1223 |
MDLN
Medline Inc
|
47.51 | 39.17B | 28.43B | 1.16B | 1.26B | 1.4457 |
ALC
Alcon Inc
|
77.82 | 39.14B | 10.40B | 980.00M | 1.61B | 1.9749 |
RMD
Resmed Inc
|
221.22 | 32.94B | 5.40B | 1.49B | 1.78B | 10.12 |
펄스 바이오 Stock (PLSE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-30 | 개시 | Mizuho | Outperform |
| 2025-07-07 | 개시 | Oppenheimer | Outperform |
| 2021-07-27 | 개시 | Stephens | Overweight |
| 2021-03-11 | 개시 | Maxim Group | Buy |
| 2021-01-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-12 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-02-14 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2019-02-25 | 개시 | H.C. Wainwright | Buy |
모두보기
펄스 바이오 주식(PLSE)의 최신 뉴스
Pulse Biosciences' nPulse Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting - Investing News Network
Pulse Biosciences (PLSE) to Showcase Innovations at Heart Rhythm Society 2026 Meeting - GuruFocus
Pulse Biosciences Starts US Trial for Cardiac Catheter System - HarianBasis.co
Pulse Biosciences (PLSE) Enrolls Its First Patients in a Pivotal Atrial Fibrillation Trial - Insider Monkey
Pulse Biosciences’ nPulse™ Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting - Yahoo Finance
Total debt per share of Pulse Biosciences, Inc. – FWB:6L8 - TradingView
Pulse Biosciences (NASDAQ:PLSE) Trading 10.1% HigherHere's Why - MarketBeat
Pulse Biosciences to Host Analyst Event on April 25, 2026 - The Joplin Globe
PLSE Stock Price, Quote & Chart | PULSE BIOSCIENCES INC (NASDAQ:PLSE) - ChartMill
Pulse Biosciences Targets Thyroid Nodules With New Device Study, Eyeing a Minimally Invasive Niche - TipRanks
Pulse Biosciences Updates 2026 Cardiac Ablation Strategy - TipRanks
Pulse Biosciences posts updated investor deck with pivotal nsPFA cardiac study details - TradingView
Pulse Biosciences (PLSE) updates investor deck with 2026 clinical goals - Stock Titan
Trading Systems Reacting to (PLSE) Volatility - Stock Traders Daily
Mizuho Securities Maintains Pulse Biosciences(PLSE.US) With Buy Rating, Maintains Target Price $30 - 富途牛牛
Income Plays: Does Pulse Biosciences Inc have strong fundamentalsPortfolio Update Summary & Reliable Price Breakout Signals - baoquankhu1.vn
Pulse Biosciences Initiates Patient Enrollment in NANOPULSE-AF Study - Yahoo Finance
Is Pulse Biosciences’ New Leadership Structure Reframing the PLSE Cardiac Therapy Commercialization Story? - Sahm
Pulse Biosciences Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Can Pulse Biosciences’ (PLSE) New AF Study and C-Suite Hires Reframe Its PFA Strategy? - Yahoo Finance
Q4 2025 Pulse Biosciences Inc Earnings Call Transcript - GuruFocus
Pulse Biosciences hires Liane Teplitsky as COO - MedTech Dive
Pulse Biosciences names Liane Teplitsky as chief operating officer By Investing.com - Investing.com Australia
Pulse Biosciences, Inc. (PLSE) stock price, news, quote and history - Yahoo Finance Singapore
Pulse Biosciences Strengthens Executive Leadership Team - Investing News Network
Pulse Biosciences appoints new COO to advance commercialization - TipRanks
Pulse Biosciences Appoints Liane Teplitsky as Chief Operating Officer Effective April 8, 2026 - Minichart
Liane R. Teplitsky named Chief Operating Officer at Pulse Biosciences - TradingView
Pulse Biosciences (PLSE) hires new COO with large inducement equity grants - Stock Titan
Pulse Biosciences Names Liane Teplitsky Chief Operating Officer - marketscreener.com
Pulse Biosciences strengthens executive leadership team - marketscreener.com
Pulse Biosciences names Liane Teplitsky as chief operating officer - Investing.com
Pulse Biosciences: Promising Catheter Technology, Weak Risk-Reward For Now - Seeking Alpha
How Low Can PLSE Really Go In A Market Crash? - Trefis
Pulse Biosciences Stock Drops 13% In A Day, Why You Shouldn Not Be Buying The Stock - Trefis
Pulse Biosciences Inc Enrolls First Patients in NANOPULSE-AF Ide Pivotal Clinical Study Evaluating nsPFA Cardiac Catheter System for Atrial Fibrillation - marketscreener.com
Pulse Biosciences Enrolls 1st Patient in nPulse PFA Tech Trial for AFib - Medical Product Outsourcing
Pulse Biosciences Inc (PLSE) Shares Gap Down to $19.14 on Apr 7 - GuruFocus
Pulse Biosciences begins pivotal atrial fibrillation trial By Investing.com - Investing.com South Africa
Pulse Biosciences Launches Pivotal NANOPULSE-AF Clinical Study - TipRanks
Pulse Biosciences, Inc. Files 8-K with SEC Detailing Company Information and Nasdaq Listing - Minichart
First patients treated in Pulse Biosciences (NASDAQ: PLSE) NANOPULSE-AF AFib trial - Stock Titan
Pulse Biosciences begins pivotal atrial fibrillation trial - Investing.com
Pulse Biosciences (NASDAQ: PLSE) recently announced that its pivotal clinical study of the Npulse™ Cardiac Catheter System for atrial fibrillation treatment (Nanopulse-Af Ide) has completed enrollment of the first group of patients. - Bitget
Pulse Biosciences enrolls first patients in Nanopulse-AF IDE pivotal clinical study evaluating nPulse(TM) cardiac catheter system for atrial fibrillation - marketscreener.com
Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation - TradingView — Track All Markets
PLSE SEC FilingsPulse Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Aug Swings: Is Pulse Biosciences Inc exposed to currency risks2026 PostEarnings & Capital Efficient Trading Techniques - baoquankhu1.vn
How Pulse Biosciences Inc (PLSE) Affects Rotational Strategy Timing - Stock Traders Daily
펄스 바이오 (PLSE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.86%
1.85%
자본화:
|
볼륨(24시간):